AKT activation and response to interferon-β in human cancer cells

Cancer Biology and Therapy

Volumn 4, Issue 7, 2005, Pages 709-715

  Lei, Hanqin ^a   Furlong, Patrick J ^a   Jin, Hee Ra ^a   Mullins, Daniel ^a   Cantor, Robert ^a   Fraker, Douglas L ^a   Spitz, Francis R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Akt; Apoptosis; Colorectal cancer; Interferon

Indexed keywords

BETA INTERFERON; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DESENSITIZATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

EID: 25144451313     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.7.1767     Document Type: Article

References (44)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. Ca: A Cancer J Clinicians 2000; 50:7-33.
2. Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: Hepatic metastasis. Seminars in Surg Oncol 1996; 12:219-52.
3. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc Nat Acad Sci USA 1995; p92:4562-6.
4. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67:227-64.
5. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47:5155-61.
6. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. Journal Interferon Cytokine Res 1997; 17:355-67.
7. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Nat Acad Sci USA1998; p95:14411-6.
8. Lengyel P. Biochemistry of interferons and their actions. Ann Rev Biochem 1982; 51:251-82.
9. Dong Z, Juang SH, Kumar R, Eue I, Xie K, Bielenberg D, Lu W, Bucana C, Yang X, Fidler IJ. Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene. Cancer Immunol Immunother 1998; 46:137-46.
10. Kaido T, Bandu MT, Maury C, Ferrantini M, Belardelli F, Gresser I. IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 1995; 60:221-9.
11. Lokshin A, Mayotte JE, Levitt ML. Mechanism of Interferon beta-induced squamous differentiation and programmed cell death in human nonsmall-cell lung cancer cell lines. J Nat Cancer Inst 1995; 87:200-12.
12. Coradini D, Pellizzaro C, Biffi A, Lombardi L, Pirronello E, Riva L, Di Fronzo G. Effect of liposome-encapsulated alpha- or beta-interferon on breast cancer cell lines. Anticancer Res 1998; 18:177-82.
13. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS, Spitz FR. Statl-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by Interferon beta in human cancer cells. Cancer Res 2003; 63:5299-307.
14. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277:27613-21.
15. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4:257-62.
16. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003; 115:145-67.
17. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; p98:10983-5.
18. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 2000; 19:5083-90.
19. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003; 56:846-53.
20. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004; 25:241-8.
21. Itoh N, Ito M, Youssef EM, Harada M, Moriya T, Kimura W, Yamakawa M, Semba S. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002; 8:3824-31.
22. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94:3127-34.
23. Rani MR, Asthagiri AR, Singh A, Sizemore N, Sathe SS, Li X, DiDonato JD, Stark GR, Ransohoff RM. A role for NF-kappa B in the induction of beta-R1 by interferon-beta. J Biol Chem 2001; 276:44365-8.
24. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 1997; 276:1418-20.
25. Ruuth K, Carlsson L, Hallberg B, Lundgren E. Interferon-alpha promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase. Biochem Biophys Res Com 2001; 284:583-6.
26. Choi EA, Lei H, Maron DJ, Mick R, Barsoum J, Yu QC, Fraker DL, Wilson JM, Spitz FR. Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin Cancer Res 2004; 10:1535-44.
27. Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98:2183-92.
28. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189:1451-60.
29. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999; 190:1155-64.
30. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343-54.
31. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
32. Kashii Y, Uchida M, Kirito K, Tanaka M, Nishijima K, Toshima M, Ando T, Koizumi K, Endoh T, Sawada K, Momoi M, Miura Y, Ozawa K, Komatsu N. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 2000; 96:941-9.
33. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277:33490-500.
34. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999; 13:2905-27.
35. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001; 276:13756-61.
36. Wang Q, Kim S, Wang X, Evers BM. Activation of NF-kappaB binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2000; 273:853-8.
37. Rani MR, Leaman DW, Han Y, Leung S, Croze E, Fish EN, Wolfman A, Ransohoff RM. Catalytically active TYK2 is essential for interferon-beta- mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 1999; 274:32507-11.
38. Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R, Manzoli L, Cocco L, Martelli AM. Constitutively active Aktl protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) upregulation. Leukemia 2003; 17:379-89.
39. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997; 272:28779-85.
40. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC, Rosen ST. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998; 91:570-6.
41. Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, Yuge K, Ohtsubo M, Ohtsuka A, Fujita T, Ohta T, Furukawa Y, Iwase S, Yamada H, Yoshimura A. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 1998; 92:1668-76.
42. Brysha M, Zhang JG, Bertolino P, Corbin JE, Alexander WS, Nicola NA, Hilton DJ, Starr R. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J Biol Chem 2001; 276:22086-9.
43. Hong F, Nguyen VA, Gao B. Tumor necrosis factor alpha attenuates Interferon alpha signaling in the liver: Involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J 2001; 15:1595-7.
44. Kessler DS, Pine R, Pfeffer LM, Levy DE, Darnell JE. Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J 1988; 7:3779-83.